淋巴细胞及宿主导向免疫治疗在重症肺炎中的作用探讨  

Role of lymphocyte and host-directed immunotherapy in severe pneumonia

作　　者：贾清清 童翔[1] 范红[1] JIA Qingqing;TONG Xiang;FAN Hong(Department of Pulmonary and Critical Care Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院呼吸与危重症医学科,成都610041

出　　处：《华西医学》2025年第4期621-625,共5页West China Medical Journal

基　　金：四川大学华西医院学科卓越发展1·3·5工程项目(2019HXFH008)。

摘　　要：重症肺炎目前仍是全球面临的重点问题之一。淋巴细胞介导的免疫失衡和细胞因子失调与肺炎重症转化及组织损伤有关,有望成为重症肺炎的潜在治疗靶点。该文对淋巴细胞在重症肺炎中的保护及致病机制进行阐述,并分别从增强宿主免疫和改善免疫病理损伤2个方面进一步介绍宿主导向免疫治疗在重症肺炎中的临床应用及研究现状,同时也介绍了免疫治疗在未来的临床转化应用过程中面临的诸多挑战,旨在为其临床诊治及研究提供新的思考方向。Severe pneumonia remains a critical global concern.The immune and cytokine imbalance mediated by lymphocytes are related to the severe transformation and tissue damage of pneumonia,and are expected to become potential therapeutic targets for severe pneumonia.This article elaborates on the protection and pathogenic mechanism of lymphocyte in severe pneumonia,and further introduces the clinical application and research status of host-directed immunotherapy in severe pneumonia from two aspects:enhancing host immunity and improving immunopathological damage.It also introduces the challenges faced by immunotherapy in the future clinical translational application,aiming to provide new thinking directions for its clinical diagnosis,treatment,and research.

关 键 词：重症肺炎 淋巴细胞 宿主导向 免疫治疗 

分 类 号：R563.1[医药卫生—呼吸系统]